

AGENDA ITEM

REPORT TO HEALTH AND WELLBEING BOARD

REPORT OF THE DIRECTOR OF PUBLIC HEALTH

Pharmaceutical Needs Assessment 2022

SUMMARY

The updated PNA is due to be published by 1st October 2022.

Following the statutory 60-day consultation a final draft has been prepared for publication.

RECOMMENDATIONS

1. To approve the final draft document for publication

DETAIL

1. The Stockton-on-Tees Health and Wellbeing Board published its first Pharmaceutical Needs Assessment on 25 March 2015, in accordance with the statutory duty to do so by 1st April 2015. The document was subsequently reviewed and a new version published 1st April 2018.
2. The legislation that describes the HWB's duties in this regard is *the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013* (as amended). As well as describing what each PNA was required to consider when they were first developed and published, these 2013 Regulations also describe how each local Assessment must be maintained by the HWB.
3. In accordance with this, a full revised assessment of the Pharmaceutical Needs Assessment was due to be renewed and published by Stockton-on-Tees Health and Wellbeing Board by 1st April 2021. Due to the Covid 19 pandemic this was deferred, and the regulations updated to require an updated PNA to be published by 1st October 2022.
4. The regulations identify that the following organisations must be consulted; the local pharmaceutical committee, the local medical committee, pharmacy and appliance contractors included in the pharmaceutical list for the HWB area, dispensing doctors in HWB area, Healthwatch, NHS trusts or NHS foundation trusts in HWB area, NHS England and NHS improvement and neighbouring Health and Well Being Boards.
5. The 2013 regulations require a report of the consultation to be included in the final version of the pharmaceutical needs assessment. (see section 7.6.2 PNA 2022)
6. The statutory consultation period for the Stockton-on-Tees HWB draft PNA was 6th April 2022 - 6th June 2022 ensuring that all statutory consultees had at least 60 days to be able to respond. A summary of the consultation was discussed at the June meeting of

the Health and Wellbeing board and the PNA document has been updated to reflect this and updates to the data.

FINANCIAL IMPLICATIONS

7. No direct financial implications

LEGAL IMPLICATIONS

8. The NHS Act (the “2006” Act), amended by the Health and Social Care Act 2012, sets out the requirements for HWBs to develop and update PNAs and gives the Department of Health and Social Care (DHSC) powers to make Regulations.

RISK ASSESSMENT

9. See legal implications above.

COMMUNITY IMPACT IMPLICATIONS

10. The aim of the PNA is to assess the pharmaceutical services required to meet the needs of the local population, taking account of demographic change and the current and future health needs in Stockton-on-Tees.

COUNCIL PLAN POLICY PRINCIPLES AND PRIORITIES

11. The PNA will be reviewed with due consideration of the Stockton-on-Tees Joint Health and Wellbeing Strategy and Council Plan.

CONSULTATION, INCLUDING WARD/COUNCILLORS

12. The review of the PNA includes a formal consultation requirement which is defined in the regulations. All relevant local stakeholders will be consulted as part of this process.

Name of Contact Officers: Jo Linton, Pharmaceutical Adviser
Tanja Braun, Consultant in Public Health
Email address: Joanne.Linton@stockton.gov.uk
Tanja.Braun@stockton.gov.uk

ⁱ Available at <http://www.legislation.gov.uk/uksi/2013/349> and hereafter referred to as the Regulations